Main Content

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

Cell Rep. Volume 29, Issue 6: p.:1675-1689, 5 November 2019, 10.1016/j.celrep.2019.09.071

Accelerating cures for children with cancer remains an immediate challenge as a result of extensive oncogenic heterogeneity between and within histologies, distinct molecular mechanisms evolving between diagnosis and relapsed disease, and limited therapeutic options. To systematically prioritize and rationally test novel agents in preclinical murine models, researchers within the Pediatric Preclinical Testing Consortium are continuously developing patient-derived xenografts (PDXs)-many of which are refractory to current standard-of-care treatments-from high-risk childhood cancers. Here, we genomically characterize 261 PDX models from 37 unique pediatric cancers; demonstrate faithful recapitulation of histologies and subtypes; and refine our understanding of relapsed disease. In addition, we use expression signatures to classify tumors for TP53 and NF1 pathway inactivation. We anticipate that these data will serve as a resource for pediatric oncology drug development and will guide rational clinical trial design for children with cancer.

Supplemental Data Files

Additional Resources

Instructions for Data Download

Open Access Data

  1. Download the appropriate manifest file from the publication page
  2. Use the manifest file to download data using the GDC Data Transfer Tool (DTT) or the GDC API

Controlled Access Data

  1. Download the appropriate manifest file from the publication page
  2. Download a token from the GDC Data Portal
  3. Use the manifest file and token to download data using the GDC DTT or the GDC API

For assistance, please contact the GDC Help Desk: